Combination of nanotechnology with vascular targeting agents for effective cancer therapy

Journal of Cellular Physiology

Volumn 233, Issue 4, 2018, Pages 2982-2992

  Jahanban Esfahlan, Rana ^a   Seidi, Khaled ^a   Banimohamad Shotorbani, Behnaz ^a,b   Jahanban Esfahlan, Ali ^c   Yousefi, Bahman ^d,e  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF TABRIZ   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Angiogenesis; Hypoxia; Microenvironment; Nanomedicine; Signaling pathways

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; BUDESONIDE; CELL MARKER; CERIUM OXIDE NANOPARTICLE; CURCUMIN; DOCETAXEL; DOXORUBICIN; ENDOSTATIN; GROWTH FACTOR; HEPARIN; IMATINIB; METHOTREXATE; MULTI WALLED NANOTUBE; NANOCARRIER; NANOMATERIAL; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT GROWTH FACTOR; SMALL INTERFERING RNA; SORAFENIB; TAXANE DERIVATIVE; URSOLIC ACID; VASCULAR TARGETING AGENT; VASCULOTROPIN; TUMOR MARKER;

ANGIOGENESIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; ENDOTHELIUM CELL; HUMAN; MALIGNANT NEOPLASM; MOLECULARLY TARGETED THERAPY; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR VASCULARIZATION; VASCULAR TUMOR; ANIMAL; BLOOD VESSEL; DRUG EFFECT; METABOLISM; NEOPLASM; PATHOLOGY; PROCEDURES; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BIOMARKERS, TUMOR; BLOOD VESSELS; HUMANS; NANOTECHNOLOGY; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 85046089535     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.26051     Document Type: Review

References (95)

1. Abbasi, M. M., Jahanban-Esfahlan, R., Monfaredan, A., Seidi, K., Hamishehkar, H., & Khiavi, M. M. (2014). Oral and IV dosages of doxorubicinmethotrexate loaded-nanoparticles inhibit progression of oral cancer by down-regulation of matrix methaloproteinase 2 expression in vivo. Asian Pacific Journal of Cancer Prevention, 15(24), 10705-10711.
2. Abbasi, M. M., Khiavi, M. M., Monfaredan, A., Hamishehkar, H., Seidi, K., & Jahanban-Esfahlan, R. (2014). DOX-MTX-NPs augment p53 mRNA expression in OSCC model in rat: Effects of IV and oral routes. Asian Pacific Journal of Cancer Prevention, 15(19), 8377-8382.
3. Abbasi, M. M., Mehdipour, M., Monfaredan, A., & Jahanban-Esfahlan, R. (2015). Hesa—A down-regulates erb/b2 oncogene expression and improves outcome of oral carcinoma in a rat model. Asian Pacific Journal of Cancer Prevention, 16(16), 6947-6951.
4. Abbasi, M. M., Monfaredan, A., Hamishehkar, H., Seidi, K., & Jahanban-Esfahlan, R. (2014). Novel DOX-MTX nanoparticles improve oral SCC clinical outcome by down regulation of lymph dissemination factor VEGF-C expression in vivo: Oral and IV modalities. Asian Pacific Journal of Cancer Prevention, 15(15), 6227-6232.
5. Arbiser, J. L., Klauber, N., Rohan, R., van Leeuwen, R., Huang, M. T., Fisher, C., Byers, H. R. (1998). Curcumin is an in vivo inhibitor of angiogenesis. Molecular Medicine, 4(6), 376-383.
6. Arvizo, R. R., Rana, S., Miranda, O. R., Bhattacharya, R., Rotello, V. M., & Mukherjee, P. (2011). Mechanism of anti-angiogenic property of gold nanoparticles: Role of nanoparticle size and surface charge. Nanomedicine, 7(5), 580-587.
7. Auerbach, W., & Auerbach, R. (1994). Angiogenesis inhibition: A review. Pharmacology & Therapeutics, 63, 265-311.
8. Augustin, H. G. (1998). Antiangiogenic tumour therapy: Will it work? TiPS, 19, 216-222.
9. Azam, F., Mehta, S., & Harris, A. L. (2010). Mechanisms of resistance to antiangiogenesis therapy. European Journal of Cancer, 46, 1323-1332.
10. Banerjee, D., Harfouche, R., & Sengupta, S. (2011). Nanotechnologymediated targeting of tumor angiogenesis. Vascular Cell, 3(1), 3.
11. Bartholomeusz, G., Cherukuri, P., Kingston, J., Cognet, L., Lemos, R., Jr, Leeuw, T. K., Powis, G. (2009). In vivo therapeutic silencing of hypoxia-inducible factor 1 alpha (HIF-1α) using single-walled carbon nanotubes noncovalently coated with siRNA. Nano Research, 2(4), 279-291.
12. Berbeco, R. I., Korideck, H., Kumar, R., Sridhar, S., Detappe, A., Ngwa, W., & Makrigiorgos, M. (2014). Targeted gold nanoparticles as vascular disrupting agents during radiation therapy. International Journal of Radiation Oncology Biology Physics, 90(1), S198.
13. Bhandarkar, S. S., & Arbiser, J. L. (2007). Curcumin as an inhibitor of angiogenesis. Advances in Experimental Medicine and Biology, 595, 185-195.
14. Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008). Active targeting schemes for nanoparticle systems in cancer therapeutics. Advanced Drug Delivery Reviews, 60(15), 1615-1626.
15. Cesca, M., Bizzaro, F., Zucchetti, M., & Giavazzi, R. (2013). Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents. Frontiers in Oncology, 3, 1-7.
16. Chaudhuri, P., Harfouche, R., Soni, S., Hentschel, D. M., & Sengupta, S. (2009). Shape effect of carbon nanovectors on angiogenesis. ACS Nano, 4(1), 574-582.
17. Chen, Q.-Y., Wang, Z.-W., Yang, X., & Wang, L. (2014). Indole conjugated silica and magnetic nanoparticles as inhibitors of HIF. Colloids and Surfaces B: Biointerfaces, 114, 158-163.
18. Chetty, C., Lakka, S. S., Bhoopathi, P., & Rao, J. S. (2010). MMP-2 alters VEGF expression via αVβ3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. International Journal of Cancer Journal International Du Cancer, 127(5), 1081-1095.
19. Cho, Y. K., Uehara, H., Young, J. R., Tyagi, P., Kompella, U. B., Zhang, X., Ambati, B. K. (2012). Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone. Investigative Ophthalmology and Visual Science, 53(4), 2328-2336.
20. Collen, A., Smorenburg, S. M., Peters, E., Lupu, F., Koolwijk, P., Van Noorden, C., & van Hinsbergh, V. W. (2000). Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Research, 60(21), 6196-6200.
21. Corti, A., & Curnis, F. (2011). Tumor vasculature targeting through NGR peptide-based drug delivery systems. Current Pharmaceutical Biotechnology, 12(8), 1128-1134.
22. Curnis, F., Fiocchi, M., Sacchi, A., Gori, A., Gasparri, A., & Corti, A. (2016). NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors. Nano Research, 9(5), 1393-1408.
23. Danhier, F., Feron, O., & Préat, V. (2010). To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release, 148(2), 135-146.
24. Das, A., Soehnlen, E., Woods, S., Hegde, R., Henry, A., Gericke, A., & Basu, S. (2011). VEGFR-2 targeted cellular delivery of doxorubicin by gold nanoparticles for potential antiangiogenic therapy. Journal of Nanoparticle Research, 13(12), 6283-6290.
25. Ding, Q., Niu, T., Yang, Y., Guo, Q., Luo, F., & Qian, Z. (2014). Preparation of curcumin-loaded poly (ester amine) nanoparticles for the treatment of anti-angiogenesis. Journal of Biomedical Nanotechnology, 10(4), 632-641.
26. Duncan, R. (2006). Polymer conjugates as anticancer nanomedicines. Nature Reviews Cancer, 6(9), 688-701.
27. El-Kenawi, A. E., & El-Remessy, A. B. (2013). Angiogenesis inhibitors in cancer therapy: Mechanistic perspective on classification and treatment rationales. British Journal of Pharmacology, 170(4), 712-729.
28. Farhang Ghahremani, M., Goossens, S., & Haigh, J. J. (2013). The p53 family and VEGF regulation: “It's complicated”. Cell Cycle, 12(9), 1331-1332.
29. Farhang Ghahremani, M., Goossens, S., Nittner, D., Bisteau, X., Bartunkova, S., Zwolinska, A., Haigh, J. J. (2013). P53 promotes VEGF expression and angiogenesis in the absence of an intact p21-Rb pathway. Cell Death & Differentiation, 20(7), 888-897.
30. Folkman, J. (2006). Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Experimental Cell Research, 312, 594-607.
31. Fujita, M., Khazenzon, N. M., Ljubimov, A. V., Lee, B.-S., Virtanen, I., Holler, E., Ljubimova, J. Y. (2006). Inhibition of laminin-8 in vivo using a novel poly (malic acid)-based carrier reduces glioma angiogenesis. Angiogenesis, 9(4), 183-191.
32. Gaya, A. M., & Rustin, G. J. (2005). Vascular disrupting agents:A new class of drug in cancer therapy. Clinical Oncology (Royal College of Radiologists), 17(4), 277-290.
33. Giri, S., Karakoti, A., Graham, R. P., Maguire, J. L., Reilly, C. M., Seal, S., Shridhar, V. (2013). Nanoceria: A rare-earth nanoparticle as a novel antiangiogenic therapeutic agent in ovarian cancer. PLoS ONE, 8(1), e54578.
34. Gurunathan, S., Lee, K. J., Kalishwaralal, K., Sheikpranbabu, S., Vaidyanathan, R., & Eom, S. H. (2009). Antiangiogenic properties of silver nanoparticles. Biomaterials, 30(31), 6341-6350.
35. Harfouche, R., Basu, S., Soni, S., Hentschel, D. M., Mashelkar, R. A., & Sengupta, S. (2009). Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis, 12(4), 325-338.
36. Hatakeyama, H., Akita, H., Ishida, E., Hashimoto, K., Kobayashi, H., Aoki, T., Harashima, H. (2007). Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. International Journal of Pharmaceutical, 342(1-2), 194-200.
37. He, X.-W., Liu, T., Xiao, Y., Feng, Y.-L., Cheng, D.-J., Tingting, G., Tingting, G. (2009). Vascular endothelial growth factor-C siRNA delivered via calcium carbonate nanoparticle effectively inhibits lymphangiogenesis and growth of colorectal cancer in vivo. Cancer Biotherapy and Radiopharmaceuticals, 24(2), 249-259.
38. Huang, K., Ma, H., Liu, J., Huo, S., Kumar, A., Wei, T., Wang, P. C. (2012). Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano, 6(5), 4483-4493.
39. Jahanban-Esfahlan, R., de la Guardia, M., Ahmadi, D., & Yousefi, B. (2017). Modulating tumor hypoxia by nanomedicine for effective cancer therapy. Journal of Cellular Physiology, https://doi.org/10.1002/jcp.25859 [Epub ahead of print].
40. Jahanban-Esfahlan, R., Seidi, K., Monfaredan, A., Shafie-Irannejad, V., Abbasi, M. M., Karimian, A., & Yousefi, B. (2017). The herbal medicine melissa officinalis extract effects on gene expression of p53, Bcl-2, Her2, VEGF-A and hTERT in human lung, breast and prostate cancer cell lines. Gene, 613, 14-19.
41. Jahanban-Esfahlan, R., Seidi, K., & Zarghami, N. (2017). Tumor vascular infarction: Prospects and challenges. International Journal of Hematology, 105(3), 244-256.
42. Jin, H., Pi, J., Yang, F., Wu, C., Cheng, X., Bai, H., Chen, Z. W. (2016). Ursolic acid-loaded chitosan nanoparticles induce potent anti-angiogenesis in tumor. Applied Microbiology and Biotechnology, 100(15), 6643-6652.
43. Kano, M. R., Komuta, Y., Iwata, C., Oka, M., Shirai, Y. T., Morishita, Y., Miyazono, K. (2009). Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-β receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Science, 100(1), 173-180.
44. Karar, J., & Maity, A. (2011). PI3K/AKT/mTOR pathway in angiogenesis. Frontiers in Molecular Neuroscience, 4, 51.
45. Kemp, M. M., Kumar, A., Mousa, S., Dyskin, E., Yalcin, M., Ajayan, P., Mousa, S. A. (2009). Gold and silver nanoparticles conjugated with heparin derivative possess anti-angiogenesis properties. Nanotechnology, 20(45), 455104.
46. Kerbel, R. S. (2000). Tumor angiogenesis: Past, present and the near future. Carcinogenesis, 21(3), 505-515.
47. Kerbel, R. S., Viloria-Petit, A., Klement, G., & Rak, J. (2000). “Accidental” anti-angiogenic drugs. Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. European Journal of Cancer, 36(10), 1248-1257.
48. Kim, S. H., Jeong, J. H., Lee, S. H., Kim, S. W., & Park, T. G. (2006). PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. Journal of Controlled Release, 116(2), 123-129.
49. Kluza, E., van der Schaft, D. W. J., Hautvast, P. A. I., Mulder, W. J. M., Mayo, K. H., Griffioen, A. W., Nicolay, K. (2010). Synergistic targeting of αvβ3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Letters, 10(1), 52-58.
50. Kompella, U. B., Bandi, N., & Ayalasomayajula, S. P. (2003). Subconjunctival nano-and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Investigative Ophthalmology and Visual Science, 44(3), 1192-1201.
51. Koushik, O., Rao, Y., Kumar, P., & Karthikeyan, R. (2016). Nano drug delivery systems to overcome cancer drug resistance—A review. Journal of Nanomedicine & Nanotechnology, 7(378), 2.
52. Kubota, Y. (2012). Tumor angiogenesis and anti-angiogenic therapy. Keio Journal of Medicine, 61(2), 47-56.
53. Kumar, R., & Yarmand-Bagheri, R. (2001). The role of HER2 in angiogenesis. Seminars in Oncology, 28(5 Suppl 16), 27-32.
54. Lai, P.-X., Chen, C.-W., Wei, S.-C., Lin, T.-Y., Jian, H.-J., Lai, I. P.-J., Tzou, W.-S. (2016). Ultrastrong trapping of VEGF by graphene oxide: Antiangiogenesis application. Biomaterials, 109, 12-22.
55. Lee, S., Jilani, S. M., Nikolova, G. V., Carpizo, D., & Iruela-Arispe, M. L. (2005). Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. The Journal of Cell Biology, 169(4), 681-691.
56. Li, M., Li, Y., Huang, X., & Lu, X. (2015). Captopril-polyethyleneimine conjugate modified gold nanoparticles for co-delivery of drug and gene in anti-angiogenesis breast cancer therapy. Journal of Biomaterials Science Polymer Edition, 26(13), 813-827.
57. Li, L., Wartchow, C. A., Danthi, S. N., Shen, Z., Dechene, N., Pease, J., Choi, H. S., Knox, S. J. (2004). A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. International Journal of Radiation Oncology Biology Physics, 58(4), 1215-1227.
58. Li, Y., Wu, Y., Huang, L., Miao, L., Zhou, J., Satterlee, A. B., & Yao, J. (2016). Sigma receptor-mediated targeted delivery of anti-angiogenic multifunctional nanodrugs for combination tumor therapy. Journal of Controlled Release, 228, 107-119.
59. Li, X., Wu, M., Pan, L., & Shi, J. (2016). Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor. International Journal of Nanomedicined, 11, 93.
60. Li, W., Zhao, X., Du, B., Li, X., Liu, S., Yang, X.-Y., Wu, X. (2016). Gold nanoparticle-mediated targeted delivery of recombinant human endostatin normalizes tumour vasculature and improves cancer therapy. Scientific Reports, 6, 30619, https://doi.org/10.1038/srep30619
61. Liu, Y., Chang, Y., Yang, C., Sang, Z., Yang, T., Ang, W., Luo, Y. (2014). Biodegradable nanoassemblies of piperlongumine display enhanced anti-angiogenesis and anti-tumor activities. Nanoscale, 6(8), 4325-4337.
62. Liu, D., Liu, F., Liu, Z., Wang, L., & Zhang, N. (2011). Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody. Molecular Pharmaceutics, 8(6), 2291-2301.
63. Long, J., Liu, W., Li, L., Wang, P., Gou, M., Huang, M., Wei, Y. (2011). Inhibiting angiogenesis by oral immunisation with poly (1-caprolactone)-poly (ethylene glycol)-poly (1-caprolactone) nanoparticle-encapsulated basic fibroblast growth factor. IET Micro & Nano Letters, 6(4), 221-225.
64. Ma, J., Liu, J., Lu, C.-W., & Cai, D.-F. (2015). Pachymic acid modified carbon nanoparticles reduced angiogenesis via inhibition of MMP-3. International Journal of Clinical and Experimental Pathology, 8(5), 5464.
65. Majidinia, M., Sadeghpour, A., Mehrzadi, S., Reiter, R. J., Khatami, N., & Yousefi, B. (2017). Melatonin: A pleiotropic molecule that modulates DNA damage response and repair pathways. Journal of Pineal Research, https://doi.org/10.1111/jpi.12416 [Epub ahead of print]
66. Majidinia, M., & Yousefi, B. (2017a). DNA repair and damage pathways in breast cancer development and therapy. DNA Repair, 54, 22-29.
67. Majidinia, M., & Yousefi, B. (2016). Long non-coding RNAs in cancer drug resistance development. DNA Repair, 45, 25-33.
68. Majidinia, M., & Yousefi, B. (2017b). Breast tumor stroma: A driving force in the development of resistance to therapies. Chemical Biology and Drug Design, 89(3), 309-318.
69. Martinelli, M., Bonezzi, K., Riccardi, E., Kuhn, E., Frapolli, R., Zucchetti, M., Giavazzi, R. (2007). Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. British Journal of Cancer, 97, 888-894.
70. McKeage, M. J., & Baguley, B. C. (2010). Disrupting established tumor blood vessels: An emerging therapeutic strategy for cancer. Cancer, 116(8), 1859-1871.
71. Montazami, N., Kheir Andish, M., Majidi, J., Yousefi, M., Yousefi, B., Mohamadnejad, L., Baradaran, B. (2015). SiRNA-mediated silencing of MDR1 reverses the resistance to oxaliplatin in SW480/OxR colon cancer cells. Cellular and Molecular Biology (Noisy-le-Grand), 61(2), 98-103.
72. Mukherjee, P., Bhattacharya, R., Wang, P., Wang, L., Basu, S., Nagy, J. A., Soker, S. (2005). Antiangiogenic properties of gold nanoparticles. Clinical Cancer Research, 11(9), 3530-3534.
73. Murugesan, S., Mousa, S. A., O’Connor, L. J., Lincoln, D. W., & Linhardt, R. J. (2007). Carbon inhibits vascular endothelial growth factor-and fibroblast growth factor-promoted angiogenesis. FEBS Letters, 581(6), 1157-1160.
74. Ngwa, W., Makrigiorgos, G. M., & Berbeco, R. I. (2012). Gold nanoparticleaided brachytherapy with vascular dose painting: Estimation of dose enhancement to the tumor endothelial cell nucleus. Medical Physics, 39(1), 392-398.
75. Pan, D., Schmieder, A. H., Wang, K., Yang, X., Senpan, A., Cui, G., Zhang, H. (2014). Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using αvβ3-targeted theranostic nanoparticles. Theranostics, 4(6), 565-578.
76. Park, I.-K., Tran, T. H., Oh, I.-H., Kim, Y.-J., Cho, K. J., Huh, K. M., & Lee, Y.-K. (2010). Ternary biomolecular nanoparticles for targeting of cancer cells and anti-angiogenesis. European Journal of Pharmaceutical Sciences, 41(1), 148-155.
77. Pike, D. B., & Ghandehari, H. (2010). HPMA copolymer-cyclic RGD conjugates for tumor targeting. Advanced Drug Delivery Reviews, 62(2), 167-183.
78. Pugh, C. W., & Ratcliffe, P. J. (2003). Regulation of angiogenesis by hypoxia: Role of the HIF system. Nature Medicine, 9(6), 677-684.
79. Ren, H., Zhu, C., Li, Z., Yang, W., & Song, E. (2014). Emodin-loaded magnesium silicate hollow nanocarriers for anti-angiogenesis treatment through inhibiting VEGF. International Journal of Molecular Sciences, 15(9), 16936-16948.
80. Ruoslahti, E. (2002). Specialization of tumour vasculature. Nature Reviews. Cancer, 2(2), 83-90.
81. Saaristo, A., Karpanen, T., & Alitalo, K. (2000). Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene, 19(53), 6122-6129.
82. Saliani, N., Darabi, M., Yousefi, B., Baradaran, B., Khaniani, M. S., Darabi, M., Hashemi, M. (2012). PPARγ agonist-induced alterations in δ6-desaturase and stearoyl-CoA desaturase 1: Role of MEK/ERK1/2 pathway. World Journal of Hepatology, 5(4), 220-225.
83. Sakurai, Y., Hatakeyama, H., Sato, Y., Hyodo, M., Akita, H., Ohga, N., Harashima, H. (2014). RNAi-mediated gene knockdown and antiangiogenic therapy of RCCs using a cyclic RGD-modified liposomalsiRNA system. Journal of Controlled Release, 173, 110-118.
84. Satchi-Fainaro, R., Mamluk, R., Wang, L., Short, S. M., Nagy, J. A., Feng, D., Folkman, J. (2005). Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell, 7(3), 251-261.
85. Satchi-Fainaro, R., Puder, M., Davies, J. W., Tran, H. T., Sampson, D A., Greene, A. K., Folkman, J. (2004). Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nature Medicine, 10(3):255-261.
86. Segal, E., Pan, H., Benayoun, L., Kopeckova, P., Shaked, Y., Kopecek, J., & Satchi-Fainaro, R. (2011). Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances. Biomaterials, 32(19), 4450-4463.
87. Seidi, K., Eatemadi, A., Mansoori, B., Jahanban-Esfahlan, R., & Farajzadeh, D. (2014). Nanomagnet-based detoxifying machine: An alternative/ complementary approach in HIV therapy. Journal of AIDS and Clinical Research, 5(5), 304.
88. Seidi, K., Jahanban-Esfahlan, R., & Zarghami, N. (2017). Tumor rim cells: From resistance to vascular targeting agents (VTAs) to complete tumor ablation. Tumor Biology, 39(3), 1-15.
89. Sengupta, S., Eavarone, D., Capila, I., Zhao, G., Watson, N., Kiziltepe, T., & Sasisekharan, R. (2005). Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature, 436(7050), 568-572.
90. Shenoi, M. M., Iltis, I., Choi, J., Koonce, N. A., Metzger, G. J., Griffin, R. J., & Bischof, J. C. (2013). Nanoparticle delivered vascular disrupting agents (VDAs): Use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy. Molecular Pharmaceutics, 10(5), 1683-1694.
91. Sun, D., Liu, Y., Yu, Q., Zhou, Y., Zhang, R., Chen, X., Liu, J. (2013). The effects of luminescent ruthenium (II) polypyridyl functionalized selenium nanoparticles on bFGF-induced angiogenesis and AKT/ERK signaling. Biomaterials, 34(1), 171-180.
92. Thorpe, P. E. (2004). Vascular targeting agents as cancer therapeutics. Clinical Cancer Research, 10(2), 415-427.
93. Wierzbicki, M., Sawosz, E., Grodzik, M., Prasek, M., Jaworski, S., & Chwalibog, A. (2013). Comparison of anti-angiogenic properties of pristine carbon nanoparticles. Nanoscale Research Letters, 8(1), 195.
94. Yang, T., Wang, Y., Li, Z., Dai, W., Yin, J., Liang, L., Zhang, Q. (2012). Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. Nanomedicine, 8(1), 81-92.
95. Zhu, J., Xu, X., Hu, M., & Qiu, L. (2015). Co-encapsulation of combretastatin-A4 phosphate and doxorubicin in polymersomes for synergistic therapy of nasopharyngeal epidermal carcinoma. Journal of Biomedical Nanotechnology, 11(6), 997-1006.